Evkeeza is now approved for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients as young as 1 year ...

AstraZeneca will launch a new online platform to make Airsupra, as well as Farxiga and Flumist, available for home delivery ...

A new targeted therapy has shown promise for a difficult-to-treat subset of lung cancer. In a multinational phase 2 trial, the oral drug sunvozertinib produced durable tumor responses in patients with ...

Recent analysis reveals Medicaid's impact on mortality, highlighting the need for diverse research methods to inform policy ...

Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more ...

The expiration of ACA tax credits threatens $32 billion in healthcare revenue, risking coverage for millions and increasing ...

MedImpact launches a performance-driven PMPM pricing model, enhancing cost predictability and accountability for health plans amid rising pharmacy expenses.

Today’s announcement builds on a previous announcement of more than 40% off the Eliquis list price, a direct-to-consumer ...

Panelists discuss how bimekizumab demonstrated significant improvements in pain scores (from baseline levels around 60/100) and fatigue measures, with meaningful percentages of patients achieving ...

FDA rejects Rexulti's approval for PTSD treatment, citing insufficient evidence of effectiveness in combination with sertraline. Otsuka and Lundbeck announced they are planning next steps.

Robert Gamble, CEO of RxBenefits, shares how Illuminate Rx does specialty, plus the areas they will continue to innovate on.

The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) ...